Edition:
United States

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.61USD
25 Jun 2018
Change (% chg)

$-0.02 (-1.23%)
Prev Close
$1.63
Open
$1.63
Day's High
$1.65
Day's Low
$1.61
Volume
28,323
Avg. Vol
229,315
52-wk High
$3.10
52-wk Low
$1.35

Select another date:

Mon, May 21 2018

BRIEF-Trevena Appoints Mark Demitrack As Chief Medical Officer

* TREVENA APPOINTS MARK A. DEMITRACK, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Trevena Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S

BRIEF-Trevena Inc And Jiangsu Nhwa Pharmaceutical Announce License Agreement For Oliceridine In China

* TREVENA INC. AND JIANGSU NHWA PHARMACEUTICAL CO. LTD ANNOUNCE LICENSE AGREEMENT FOR OLICERIDINE IN CHINA

BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018

* TREVENA SAYS ON APRIL 9, ROBERTO CUCA, CHIEF FINANCIAL OFFICER OF CO FORMALLY NOTIFIED CO OF HIS RESIGNATION, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source text: (https://bit.ly/2GVszsP) Further company coverage:

BRIEF-Trevena Reports Q4 Loss Per Share $0.24

* COMPANY EXPECTS THAT EXPENSES WILL DECREASE IN 2018 COMPARED TO 2017

BRIEF-Trevena Inc Says FDA Indicated To Co That PDUFA Date For Olinvo NDA Is Nov 2‍​

* TREVENA INC - ON JAN 5, FDA INDICATED TO THE CO THAT PDUFA REVIEW DATE FOR OLINVO NDA IS NOV 2‍​

BRIEF-Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection

* TREVENA ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR OLINVO (OLICERIDINE) INJECTION

Select another date: